Global Liquid Biopsy Market is projected to reach USD 4.5 billion by 2022

Liquid Biopsy Market

Global Liquid Biopsy Market Overview:

A liquid biopsy is a minimally invasive test for assessing maximum cancers genetic fame based totally on the assessment of circulating unfastened DNA (cfDNA) this is present in the plasma thing of blood. One manner that tumors release biomarker records is through tumor cell necrosis and the release of lifeless cells or cell fragments. Those cells are engulfed by using phagocytes that affects the tumor cellular DNA, and then launched into the bloodstream. Because cfDNA is derived from the tumor cells, cfDNA may be analyzed for the equal genetic aberrations found in tumors, which consist of mutation, amplification, chromosomal rearrangement, and hypermethylation. The global Liquid Biopsy market is predicted to increase at a CAGR of 24.2% within the forecast period to attain a value of USD 4.5 billion by 2022 from USD 1.5 billion in 2017.

Get Sample Brochure of the Report @

Drivers and Restraints:

The advantages of imposing liquid biopsy over traditional strategies of stable tissue biopsy are anticipated to enhance the increase of the market. The benefits of liquid biopsies, along with minimally invasiveness and metastatic relapse evaluation are anticipated to raise the demand for those tests. Moreover, the growth in disposable profits among cancer patients, a surge in the incidence of cancer cases, and affected person’s choice for minimally invasive remedies are expected to fuel the market growth. Increase in healthcare expenditure within the international locations and use of liquid biopsy assessments to deal with uncommon cancers are predicted to offer multiple possibilities for the market growth.

However, this growth is limited due to options for liquid biopsies, and unclear reimbursement and law scenario.

Geographic Segmentation

Geographically the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. All principal action within the field of liquid biopsy is expected to emerge from North America and Europe area over the forecast period. But, growing investment for personal public partnerships in a subject of cancer studies is expected to fuel the Asia-Pacific market.

Key Players of Global Liquid Biopsy Market:

The main players of the market include Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.

Browse report brief and TOC @

Scope of the report

The report offers a comprehensive analysis of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along this, the factors influential in effecting the market dynamics and trends are discussed in detail at the product level. Further, the performance of the market at the regional and country-level is assessed and the prospects with high growth potential are identified and debated.

The key players in the industry are profiled providing insights on their financial performance, market position and growth strategies. Comparative analysis on prime strategical activities of the market players delineating the key developments like mergers & acquisitions, collaborations and an evaluation of the competitive environment within the industry are provided. The report also offers a broad outlook of the market along with recommendations from industry experts on the opportunities for investment activity.

What else? Apart from the syndicated report, our in-house team has an expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.

Inquire Before Buying @

About Us:

Research Cosmos is a provider of standard and customized market research, business intelligence and consulting services across more than 100 domains in different industries of the world. We host the trending market reports of the world’s top-notch publishing companies, offering services to a wide range of customers from students to fortune 500 companies and discloses the hidden opportunities in every leading industry of the world.

Contact Us: 

Kevin Stewart
Global Sales Manager
Research Cosmos
+1 888 709 8757

About Anand Sai 87 Articles
Anand Sai, A Research Consultant with 5+years of experience in handling research operations of various domains.

Be the first to comment

Leave a Reply